Exelixis Inc. will unveil data from a late-stage trial of its cancer-fighting drug cabozantinib about three months later than originally expected.
The South San Francisco drug developer (NASDAQ: EXEL) said it needs more time to reach a pre-specified number of “events” — deaths or showing how long patients live without the disease progressing — with medullary thyroid cancer patients before it can unbind data and report top-line results of the study.
No comments:
Post a Comment